CD44 and cerebral infarction: A recent animal experiment showed that PCSK9 inhibitor evolocumab improved neurobehavioral functions and reduced cerebral infarct volumes, which may be mediated by attenuating neuroinflammation through activation of the GPNMB/CD44 pathway (40).